- Home
- TBBK vs ZLAB Comparison
TBBK vs ZLAB Comparison
Compare TBBK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBBK | ZLAB |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.0B |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TBBK | ZLAB |
|---|---|---|
| Price | $68.85 | $17.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $69.33 | $57.22 |
| AVG Volume (30 Days) | 544.0K | ★ 840.9K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.10 | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | ★ $523,163,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $26.16 |
| Revenue Next Year | $7.37 | $30.62 |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | 10.84 | ★ 24.14 |
| 52 Week Low | $40.51 | $16.82 |
| 52 Week High | $81.65 | $44.34 |
Technical Indicators
Market Signals| Indicator | TBBK | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 34.99 |
| Support Level | $66.85 | $17.50 |
| Resistance Level | $72.00 | $19.01 |
| Average True Range (ATR) | 1.83 | 0.61 |
| MACD | 0.14 | 0.27 |
| Stochastic Oscillator | 47.15 | 35.16 |
Price Performance
Historical ComparisonAbout TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.